Migraine drug up for FDA review

Biotech company says approval would result in increased workforce

By Luther Turmelle luther.turmelle@hearstmediact.com

NEW HAVEN — A bio­pharmaceutical company based in the city said in a regulatory filing last week that the federal Food and Drug Administration has accepted its new drug application for treatment and prevention of migraine headaches. The Oct. 3 filing...

Read latest New Haven Register (New Haven, CT) online.

Online newspapers at PressDisplay.